62 related articles for article (PubMed ID: 18605086)
1. Detection of the MDR1 P-glycoprotein expression and function.
Mechetner E
Methods Mol Biol; 2007; 378():175-93. PubMed ID: 18605086
[TBL] [Abstract][Full Text] [Related]
2. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
3. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.
Park SW; Lomri N; Simeoni LA; Fruehauf JP; Mechetner E
Cytometry A; 2003 Jun; 53(2):67-78. PubMed ID: 12766968
[TBL] [Abstract][Full Text] [Related]
4. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer.
Krasznai ZT; Friedländer E; Nagy A; Szabó G; Vereb G; Goda K; Hernádi Z
Anticancer Res; 2005; 25(2A):1187-92. PubMed ID: 15868961
[TBL] [Abstract][Full Text] [Related]
5. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein.
Lehne G; De Angelis P; Clausen OP; Egeland T; Tsuruo T; Rugstad HE
Cytometry; 1995 Jul; 20(3):228-37. PubMed ID: 7587708
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.
Raghu G; Park SW; Roninson IB; Mechetner EB
Exp Hematol; 1996 Aug; 24(10):1258-64. PubMed ID: 8765502
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein expression in the squamous cell carcinoma of the tongue base.
Rabkin D; Chhieng DC; Miller MB; Jennings T; Feustel P; Steiniger J; Parnes SM
Laryngoscope; 1995 Dec; 105(12 Pt 1):1294-9. PubMed ID: 8523980
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
9. Expression of mdr1/P-glycoprotein and p110 in neuroblastoma.
Ramani P; Dewchand H
J Pathol; 1995 Jan; 175(1):13-22. PubMed ID: 7891222
[TBL] [Abstract][Full Text] [Related]
10. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Beck WT; Grogan TM; Willman CL; Cordon-Cardo C; Parham DM; Kuttesch JF; Andreeff M; Bates SE; Berard CW; Boyett JM; Brophy NA; Broxterman HJ; Chan HS; Dalton WS; Dietel M; Fojo AT; Gascoyne RD; Head D; Houghton PJ; Srivastava DK; Lehnert M; Leith CP; Paietta E; Pavelic ZP; Weinstein R
Cancer Res; 1996 Jul; 56(13):3010-20. PubMed ID: 8674056
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.
Sivapackiam J; Harpstrite SE; Prior JL; Gu H; Rath NP; Sharma V
Dalton Trans; 2010 Jul; 39(25):5842-50. PubMed ID: 20505882
[TBL] [Abstract][Full Text] [Related]
12. Quantitative determination of the MDR-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique.
Ferrand VL; Montero Julian FA; Chauvet MM; Hirn MH; Bourdeaux MJ
Cytometry; 1996 Feb; 23(2):120-5. PubMed ID: 8742170
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
14. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
15. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.
Kopnin BP; Stromskaya TP; Kondratov RV; Ossovskaya VS; Pugacheva EN; Rybalkina EY; Khokhlova OA; Chumakov PM
Oncol Res; 1995; 7(6):299-306. PubMed ID: 8527864
[TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance by RNA interference.
Stege A; Krühn A; Lage H
Methods Mol Biol; 2010; 596():447-65. PubMed ID: 19949936
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein: clinical significance and methods of analysis.
van der Heyden S; Gheuens E; DeBruijn E; Van Oosterom A; Maes R
Crit Rev Clin Lab Sci; 1995; 32(3):221-64. PubMed ID: 7495497
[TBL] [Abstract][Full Text] [Related]
18. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
20. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
